 |
|
Cholecystokinin Tetrapeptide Induces Panic-like Attacks in Healthy VolunteersPreliminary Findings
Claude de Montigny, MD, PhD, FRCPC
Arch Gen Psychiatry. 1989;46(6):511-517.
Abstract
• A total of 31 intravenous injections of the tetrapeptide cholecystokinin (30-33) were carried out in ten healthy subjects. In seven subjects, cholecystokinin-4 provoked a short-lasting (one to four minutes) panic-like attack (an intense unexplainable fear) at doses between 20 and 100 µg. In the other three subjects, doses of 80 to 100 µ induced severe anxiety, but no panic-like attack. All subjects experienced severe gastrointestinal symptoms. Pretreatment with lorazepam, but not with meprobamate or naloxone, prevented the psychic effects of cholecystokinin-4 in subjects who had experienced a panic-like attack with the same dose of this peptide. Following the peptide injection, levels of plasma free catecholamines, lactate, and glucose were unchanged, whereas levels of plasma cortisol and prolactin were increased. The intravenous injection of the sulfated cholecystokinin octapeptide (26-33) in two subjects (doses of 35 and 40 µg, respectively) produced severe gastrointestinal symptoms, but failed to induce any anxiety or panic-like attacks. These preliminary findings suggest that cholecystokinin-4 may have a panicinducing effect. It remains to be established if this peptide exerts this effect via a direct activation of central cholecystokinin receptors.
Author Affiliations
From the Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal.
Footnotes
Accepted for publication Sept 19, 1988.
Reprint requests to Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, 1033, ave des Pins ouest, Montreal (Quebec), Canada H3A1A1 (Dr de Montigny).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: Investigation of neural correlates with BOLD MRI
Schunck et al.
J Psychopharmacol 2011;25:52-59.
ABSTRACT
Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs
Gilles and Luthringer
J Psychopharmacol 2007;21:272-282.
ABSTRACT
Induced Panic Attacks Shift {gamma}-Aminobutyric Acid Type A Receptor Modulatory Neuroactive Steroid Composition in Patients With Panic Disorder: Preliminary Results
Strohle et al.
Arch Gen Psychiatry 2003;60:161-168.
ABSTRACT
| FULL TEXT
Enhanced Cortical Extracellular Levels of Cholecystokinin-Like Material in a Model of Anticipation of Social Defeat in the Rat
Becker et al.
J. Neurosci. 2001;21:262-269.
ABSTRACT
| FULL TEXT
International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors
Noble et al.
Pharmacol. Rev. 1999;51:745-781.
ABSTRACT
| FULL TEXT
The cholecystokinin hypothesis of panic and anxiety disorders: a review
Bradwejn et al.
J Psychopharmacol 1992;6:345-351.
ABSTRACT
Enhanced Sensitivity to Cholecystokinin Tetrapeptide in Panic Disorder: Clinical and Behavioral Findings
Bradwejn et al.
Arch Gen Psychiatry 1991;48:603-610.
ABSTRACT
Cholecystokinin-4 and Panic
ABELSON and NESSE
Arch Gen Psychiatry 1990;47:395-395.
ABSTRACT
|
